Treatment FailureNCT03369093
RCT of Efficacy of Amoxicillin Over Ampicillin on Severe Pneumonia
A study testing Amoxicillin in people with Treatment Failure and Lethargy, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.
Trial summary
Burden: Pneumonia remains the leading infectious cause of death accounting for 920,000 children under five around the world. This means a loss of over 2,500 child lives every day, or over 100 every hour. Since 2000, the number of child deaths caused by pneumonia has decreased by 47 percent. Read more about this study
- Who is it for?
- Ages 2 months to 5 years
- Conditions the study is for
- Treatment Failure, Lethargy, Altered Mental Status
- What is being tested?
- Amoxicillin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 308 participants
- Where
- 1 siteBangladesh
- Study dates
- 1 Jan 2018to 31 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 months to 5 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- 1. WHO classified severe pneumonia
Who cannot join
- Very sick children require mechanical ventilation
- Children with any congenital or structural defect
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy of Two Doses of Parenteral Amoxicillin Plus Single Dose Gentamicin Compared to Four Doses of Parenteral Ampicillin Plus Single Dose Gentamicin in Managing Children Hospitalized With WHO Classified Severe Pneumonia: a RCT
Burden: Pneumonia remains the leading infectious cause of death accounting for 920,000 children under five around the world. This means a loss of over 2,500 child lives every day, or over 100 every hour. Since 2000, the number of child deaths caused by pneumonia has decreased by 47 percent. The tremendous progress made is due in part to the rapid roll-out of vaccines, better nutrition, and improved care-seeking and treatment for symptoms. However, pneumonia hasn't declined as quickly as other diseases such as malaria (58%), HIV/AIDS (61%), and measles (85%).
Knowledge gap: The Lancet Series on Childhood Pneumonia and Diarrhea has reported that case management is one of the three most effective interventions to reduce pneumonia deaths in children. It is also noted that the cost-effectiveness of these interventions in the national health system needs urgent assessment. It was suggested to find out means to reduce hospital stay without compromising the quality of care.
Read more
Relevance: The main purpose of the study is to compare the efficacy of two doses of parenteral Amoxicillin plus single-dose Gentamicin compared to four doses of parenteral Ampicillin plus single-dose Gentamicin. After 72 hours of treatment injectable Amoxicillin or injection Ampicillin will be switched to or replaced by oral Amoxicillin and will be discharged with an advice to attend to Ambulatory Care Unit (ACU) to receive a once-daily dose of injection Gentamicin for a total of 5 days. It is anticipated that this modified therapy will reduce the hospitalization stay of children with severe pneumonia and would therefore be relevant in countries with the resource-poor settings. By reducing the hospitalization period, this therapy has the potentials to reduce hospital-acquired infection.
Hypothesis (if any): Rate of treatment failure with two doses of injectable Amoxicillin plus single-dose Gentamicin will be no more than that of four doses of injectable Ampicillin plus single-dose Gentamicin in the management of children between 2 months to 59 months hospitalized for WHO classified severe pneumonia.
Read the detailed description
Severe pneumonia is a serious infection in children which requires timely intervention. Management of severe pneumonia is done by appropriate antibiotics and supportive care. WHO recommendation is to use injection ampicillin four times a day for 3-5 days and injection gentamicin once a day for 3-5 days in children with severe pneumonia. In the study, the investigators want to compare the response of injection ampicillin with another similar and equally effective antibiotic (amoxicillin). The reason for choosing amoxicillin is that the dose is two times a day and it is cost-effective and reduces chances of nosocomial infection. The response of the drugs will be compared by the time difference of clinical improvement of the patients or time difference of disappearance of the sign and symptoms on admission. The investigators are interested to compare the recovery time from the illness as well as treatment failure in both groups. In that way, the investigators will be able to develop a better treatment for pneumonia in children in low-cost settings.
The study will be an open-label, randomized, controlled intervention in children between two months to 59 months admitted to Dhaka Hospital of icddr,b. Investigators will use sealed envelopes to randomly assign the children to either treatment arm. In the first arm children will receive 2 daily doses of parenteral Amoxicillin and a single daily dose of parenteral Gentamicin; and in 2nd arm, children will receive 4 daily doses of parenteral Ampicillin and a single daily dose of parenteral Gentamicin. After 72 hours of treatment, injection Amoxicillin and injection Ampicillin will be replaced with oral Amoxicillin but injection gentamicin will be continued for a total of 5 days in one daily dose. During this time participants will be suggested to discharge from the hospital and attain to the Ambulatory care unit for getting a once-daily dose of injection of Gentamicin. Both the treatment arm will continue for 5 days.
During the study period, participants in both study arms will also receive standardized hospital management for other co-morbidities-such as diarrhea, malnutrition, and any other complications. Hypoxia will be managed by B-CPAP through a nasal cannula.
Any participants will be declared "Treatment failure" who show the persistence of danger signs after 48 hours or develop new danger signs within 24 hours of initiation of antibiotic treatment. If a participant needs mechanical ventilation, dies at any time during a hospital stay, or left the hospital against medical advice will be also declared as a treatment failure.
Participants from either study group who develops the features of "treatment failure" should be rescued with the second-line antibiotic regimen, which is injection ceftriaxone and injection levofloxacin.
Monitoring of the children with severe pneumonia The following parameters should be routinely monitored in every child with severe pneumonia. Special attention should be given to participants receiving I/V fluid therapy and those with SAM. Such as: Heart rate, respiratory rate, temperature, respiratory pattern including chest recession, lower chest wall indrawing, use of accessory muscles, the establishment of oral feeding, liver size, oxygen saturation level, chest auscultation: (rales, rhonchi, bilateral basal crepitation, pleural rub), fluid and calorie intake.
Participants on oxygen therapy should have at least 3-4 hourly observations of all the above parameters and participants without getting oxygen should be observed at least 2 hourly by the study nurses. All the patients should be evaluated by the physicians at least 12 hourly.
Signs of Improvement:
In absence of complications, within 2 days of initiation of treatment, there should be signs of improvement i ) breathing rate within normal limit; ii) absence of the lower chest wall in-drawing; iii) less to no fever; iv) improved ability to eat and drink, and v) better oxygen saturation without assistance.
Discharge criteria
- Respiratory distress has resolved
- Oxygen saturation > 90%
- Feeding well
- Able to take oral medication or have completed a course of parenteral antibiotics
- The parents understand the signs of pneumonia, risk factors, and when to return
The study objective is to compare the efficacy of two doses of injectable Amoxicillin plus single-dose injectable Gentamicin compared to four doses of injectable Ampicillin plus single-dose injectable Gentamicin in the management of participants hospitalized with WHO pneumonia.
Secondary objectives are to compare time to resolution of danger signs of pneumonia, length of hospital stay, mortality rate, rate of complication requiring mechanical ventilation, and rate of multiorgan or renal or cardiac failure between the two treatment groups.
Children more than 2 months to less than 59 months will be enrolled in the study, if participants have a history of cough or difficulty in breathing and WHO classified severe pneumonia plus at least two of the following:
- Central cyanosis or oxygen saturation <90% on pulse oxymetry ii) Severe respiratory distress (e.g. grunting, very severe chest indrawing) iii) Signs of pneumonia with a general danger sign: inability to breastfeed or drink; lethargy or reduced level of consciousness; convulsion iv) In addition, some or all of the other signs of pneumonia may be present, such as:
- Signs of pneumonia [age specific fast breathing( Annex 1)]
- Chest indrawing: lower chest wall indrawing
- Chest auscultation signs: (any one)
- Decreased breath sounds
- Bronchial breath sounds
- Crackles
- Abnormal vocal resonance (decreased over a pleural effusion or empyema, increased over lobar consolidation)
- Pleural rub
Participants with a life-threatening condition that required immediately assisted ventilation or referring to an outside hospital (such as septic shock, cardiac arrest, apnea, respiratory failure, etc.) will be excluded from the study. Children with uncorrected cyanotic CHD, hypercapnia (PCO2 > 60mm of Hg), status asthmaticus and upper-airway obstruction, preterm baby (but not ex-preterm), and those for who inform consent can't be secured from their parents/ care-givers. Caregivers presented with any drug container of antibiotics or prescription showing getting antibiotics will be excluded.
Sample size calculation:
[For two-sample comparison of proportion (non-inferiority)]
Null hypothesis: p2-p1≤ δ (inferior), where: pi (entered in command) is the overall proportion of participants expect to experience the outcome of the treatments are non-inferior, and delta is the smallest change in proportions between groups (p2 - p1) which would still be clinically important.
Assumptions:
power = 0.8; alpha = 0.025 (one-sided); pi = 0.50; delta = 0.16 Estimated required sample size (per group) = 154,
Total sample is 308
This study will be conducted at the Dhaka Hospital of icddr,b, Dhaka, Bangladesh. This hospital is located in Dhaka city, the capital of Bangladesh. It provides care and treatment to around 110,000 diarrheal patients with or without associated complications and with or without other health problems each year. The vast majority of the patients come from poor socio-economic backgrounds from urban and peri-urban Dhaka, the capital city of Bangladesh.
Patients attending this hospital are first assessed by an experienced triage nurse, which includes assessment of the type of diarrhea and degree of dehydration, and presence of other health problems including ALRI/ pneumonia, severe malnutrition, impaired mental status (convulsion), and sepsis. The non-diarrhoeal patients have been redirected to other appropriate hospitals in the city. Based on an assessment of diarrhoeal patients, those with uncomplicated illness without signs of dehydration are referred to the Out-Patient Department (OPD) for 4-5 hours of observation, maintenance of hydration using ORS solution, and for provision of health education to the mothers/caregivers. Those with some and severe dehydration but without any associated health problems are admitted to Short Stay Ward (SSW) for correction of dehydration and maintenance of hydration using ORS and/or intravenous fluids, provision of antimicrobial therapy as appropriate, with an average stay of 24 hours. Those with associated complications of diarrhea and/or associated health problems are referred to a physician for assessing the need for admission to either the Longer Stay Ward (LSW) or Acute Respiratory Ward (ARI) or to the Intensive Care Word (ICU) depending on the clinical severity. The usual associated conditions include difficult respiration, cyanosis, apnoea, hypothermia or hyperthermia, marked lethargy or comatose condition, poor peripheral perfusion not attributable to severe dehydration. Participants hospitalized in SSW are assessed by hospital clinicians for possible admission to LSW and further workup and management. After admission to the LSW/ARI/SCU, the attending physician will obtain medical history, performs a thorough clinical examination, makes a problem list including differential diagnoses for each of them, arranges for required laboratory workups, and develops the treatment plan following standard guidelines of the hospital. Investigators will also perform bedside procedures such as sampling blood, performing lumbar punctures, etc. Oxygen saturation is determined by pulse oximeter when necessary, and blood glucose estimated by bedside Gluco Check machine in nearly all patients admitted to the LSW/ARI /SCU.
- Conditions
- Treatment Failure, Lethargy, Altered Mental Status, Convulsion, Non-Epileptic, Hypoxia, Feeding; Difficult, Newborn
- Being tested
- Amoxicillin
- Keywords
- RCT, severe pneumonia, amoxicillin, under five
- Medical subject headings
- Lethargy, Seizures, Hypoxia, Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AmoxicillinDrug
Also called no other intervention
Twice daily doses of injectable amoxicillin
| Study group | Role | What they receive |
|---|---|---|
| Ampicillin arm | Active comparator | Ampicillin arm: Patients will receive four doses of parenteral Ampicillin and single dose of Gentamicin daily for 3-5 days Receives: Drug: Amoxicillin |
| Amoxicillin arm | Experimental | Amoxicillin arm: Patients will receive two doses of Amoxicillin and single dose of Gentamicin daily for 3-5 days Receives: Drug: Amoxicillin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment failure
Persistence of danger signs of severe pneumonia such as hypoxia, feeding difficulty, abnormal mentation after 48 hours or new appearance of danger sign within 24 hours
Measured: within 48 hours
Secondary outcomes (4)
Time of resolution or recovery from pneumonia period for pneumonia
Recovery from features of pneumonia in terms of respiratory distress, abnormal chest auscultation finding
Measured: 48 hours
Total length of hospitalization
Period of hospitalization
Measured: 3-5 days
Nosocomial infection
any hospital acquired infection proven by laboratory facility
Measured: 7 days
Post discharge morbidity
Follow up over phone to get information of any mild illness at home after discharge
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2017
- Study start1 Jan 2018
- Primary completion31 Oct 2019
- Study completion31 Dec 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Treatment FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Investigators have completed the enrollment of 308 participants by the study endline. All the Serious adverse events have been reported appropriately to the Ethical Review Committee and the Data Safety and Monitoring Board (DSMB)
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 308 participants (actual)
Sponsor and investigators
- Lead sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lubaba Shahrin, MBBS, FCPS, Principal investigator, Dhaka Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03369093
- Sponsor's protocol ID
- PR-17061
- Status last verified
- Jul 2021
- First submitted
- 25 Sep 2017
- Last updated
- 16 Jul 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Shahrin L, Chisti MJ, Shahid ASMSB, Rahman ASMMH, Islam MZ, Afroze F, Huq S, Ahmed T. Injectable Amoxicillin Versus Injectable Ampicillin Plus Gentamicin in the Treatment of Severe Pneumonia in Children Aged 2 to 59 Months: Protocol for an Open-Label Randomized Controlled Trial. JMIR Res Protoc. 2020 Nov 2;9(11):e17735. doi: 10.2196/17735.
PubMed 33136058
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Two Doses of Parenteral Amoxicillin Plus Single Dose Gentamicin Compared to Four Doses of Parenteral Ampicillin Plus Single Dose Gentamicin in Managing Children Hospitalized With WHO Classified Severe Pneumonia: a RCT
- ClinicalTrials.gov ID
- NCT03369093
- Acronym / sponsor ID
- PR-17061
- Conditions
- Treatment Failure, Lethargy, Altered Mental Status, Convulsion, Non-Epileptic, Hypoxia, Feeding; Difficult, Newborn
- Keywords
- RCT, severe pneumonia, amoxicillin, under five
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 308 participants (actual)
- Lead sponsor
- International Centre for Diarrhoeal Disease Research, BangladeshUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 31 Oct 2019 (actual)
- Study completion
- 31 Dec 2019 (actual)
- First posted
- 11 Dec 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Burden: Pneumonia remains the leading infectious cause of death accounting for 920,000 children under five around the world. This means a loss of over 2,500 child lives every day, or over 100 every hour. Since 2000, the number of child deaths caused by pneumonia has decreased by 47 percent. The tremendous progress made is due in part to the rapid roll-out of vaccines, better nutrition, and improved care-seeking and treatment for symptoms. However, pneumonia hasn't declined as quickly as other diseases such as malaria (58%), HIV/AIDS (61%), and measles (85%).
Knowledge gap: The Lancet Series on Childhood Pneumonia and Diarrhea has reported that case management is one of the three most effective interventions to reduce pneumonia deaths in children. It is also noted that the cost-effectiveness of these interventions in the national health system needs urgent assessment. It was suggested to find out means to reduce hospital stay without compromising the quality of care.
Relevance: The main purpose of the study is to compare the efficacy of two doses of parenteral Amoxicillin plus single-dose Gentamicin compared to four doses of parenteral Ampicillin plus single-dose Gentamicin. After 72 hours of treatment injectable Amoxicillin or injection Ampicillin will be switched to or replaced by oral Amoxicillin and will be discharged with an advice to attend to Ambulatory Care Unit (ACU) to receive a once-daily dose of injection Gentamicin for a total of 5 days. It is anticipated that this modified therapy will reduce the hospitalization stay of children with severe pneumonia and would therefore be relevant in countries with the resource-poor settings. By reducing the hospitalization period, this therapy has the potentials to reduce hospital-acquired infection.
Hypothesis (if any): Rate of treatment failure with two doses of injectable Amoxicillin plus single-dose Gentamicin will be no more than that of four doses of injectable Ampicillin plus single-dose Gentamicin in the management of children between 2 months to 59 months hospitalized for WHO classified severe pneumonia.
Detailed description
Severe pneumonia is a serious infection in children which requires timely intervention. Management of severe pneumonia is done by appropriate antibiotics and supportive care. WHO recommendation is to use injection ampicillin four times a day for 3-5 days and injection gentamicin once a day for 3-5 days in children with severe pneumonia. In the study, the investigators want to compare the response of injection ampicillin with another similar and equally effective antibiotic (amoxicillin). The reason for choosing amoxicillin is that the dose is two times a day and it is cost-effective and reduces chances of nosocomial infection. The response of the drugs will be compared by the time difference of clinical improvement of the patients or time difference of disappearance of the sign and symptoms on admission. The investigators are interested to compare the recovery time from the illness as well as treatment failure in both groups. In that way, the investigators will be able to develop a better treatment for pneumonia in children in low-cost settings.
The study will be an open-label, randomized, controlled intervention in children between two months to 59 months admitted to Dhaka Hospital of icddr,b. Investigators will use sealed envelopes to randomly assign the children to either treatment arm. In the first arm children will receive 2 daily doses of parenteral Amoxicillin and a single daily dose of parenteral Gentamicin; and in 2nd arm, children will receive 4 daily doses of parenteral Ampicillin and a single daily dose of parenteral Gentamicin. After 72 hours of treatment, injection Amoxicillin and injection Ampicillin will be replaced with oral Amoxicillin but injection gentamicin will be continued for a total of 5 days in one daily dose. During this time participants will be suggested to discharge from the hospital and attain to the Ambulatory care unit for getting a once-daily dose of injection of Gentamicin. Both the treatment arm will continue for 5 days.
During the study period, participants in both study arms will also receive standardized hospital management for other co-morbidities-such as diarrhea, malnutrition, and any other complications. Hypoxia will be managed by B-CPAP through a nasal cannula.
Any participants will be declared "Treatment failure" who show the persistence of danger signs after 48 hours or develop new danger signs within 24 hours of initiation of antibiotic treatment. If a participant needs mechanical ventilation, dies at any time during a hospital stay, or left the hospital against medical advice will be also declared as a treatment failure.
Participants from either study group who develops the features of "treatment failure" should be rescued with the second-line antibiotic regimen, which is injection ceftriaxone and injection levofloxacin.
Monitoring of the children with severe pneumonia The following parameters should be routinely monitored in every child with severe pneumonia. Special attention should be given to participants receiving I/V fluid therapy and those with SAM. Such as: Heart rate, respiratory rate, temperature, respiratory pattern including chest recession, lower chest wall indrawing, use of accessory muscles, the establishment of oral feeding, liver size, oxygen saturation level, chest auscultation: (rales, rhonchi, bilateral basal crepitation, pleural rub), fluid and calorie intake.
Participants on oxygen therapy should have at least 3-4 hourly observations of all the above parameters and participants without getting oxygen should be observed at least 2 hourly by the study nurses. All the patients should be evaluated by the physicians at least 12 hourly.
Signs of Improvement:
In absence of complications, within 2 days of initiation of treatment, there should be signs of improvement i ) breathing rate within normal limit; ii) absence of the lower chest wall in-drawing; iii) less to no fever; iv) improved ability to eat and drink, and v) better oxygen saturation without assistance.
Discharge criteria
- Respiratory distress has resolved
- Oxygen saturation > 90%
- Feeding well
- Able to take oral medication or have completed a course of parenteral antibiotics
- The parents understand the signs of pneumonia, risk factors, and when to return
The study objective is to compare the efficacy of two doses of injectable Amoxicillin plus single-dose injectable Gentamicin compared to four doses of injectable Ampicillin plus single-dose injectable Gentamicin in the management of participants hospitalized with WHO pneumonia.
Secondary objectives are to compare time to resolution of danger signs of pneumonia, length of hospital stay, mortality rate, rate of complication requiring mechanical ventilation, and rate of multiorgan or renal or cardiac failure between the two treatment groups.
Children more than 2 months to less than 59 months will be enrolled in the study, if participants have a history of cough or difficulty in breathing and WHO classified severe pneumonia plus at least two of the following:
- Central cyanosis or oxygen saturation <90% on pulse oxymetry ii) Severe respiratory distress (e.g. grunting, very severe chest indrawing) iii) Signs of pneumonia with a general danger sign: inability to breastfeed or drink; lethargy or reduced level of consciousness; convulsion iv) In addition, some or all of the other signs of pneumonia may be present, such as:
- Signs of pneumonia [age specific fast breathing( Annex 1)]
- Chest indrawing: lower chest wall indrawing
- Chest auscultation signs: (any one)
- Decreased breath sounds
- Bronchial breath sounds
- Crackles
- Abnormal vocal resonance (decreased over a pleural effusion or empyema, increased over lobar consolidation)
- Pleural rub
Participants with a life-threatening condition that required immediately assisted ventilation or referring to an outside hospital (such as septic shock, cardiac arrest, apnea, respiratory failure, etc.) will be excluded from the study. Children with uncorrected cyanotic CHD, hypercapnia (PCO2 > 60mm of Hg), status asthmaticus and upper-airway obstruction, preterm baby (but not ex-preterm), and those for who inform consent can't be secured from their parents/ care-givers. Caregivers presented with any drug container of antibiotics or prescription showing getting antibiotics will be excluded.
Sample size calculation:
[For two-sample comparison of proportion (non-inferiority)]
Null hypothesis: p2-p1≤ δ (inferior), where: pi (entered in command) is the overall proportion of participants expect to experience the outcome of the treatments are non-inferior, and delta is the smallest change in proportions between groups (p2 - p1) which would still be clinically important.
Assumptions:
power = 0.8; alpha = 0.025 (one-sided); pi = 0.50; delta = 0.16 Estimated required sample size (per group) = 154,
Total sample is 308
This study will be conducted at the Dhaka Hospital of icddr,b, Dhaka, Bangladesh. This hospital is located in Dhaka city, the capital of Bangladesh. It provides care and treatment to around 110,000 diarrheal patients with or without associated complications and with or without other health problems each year. The vast majority of the patients come from poor socio-economic backgrounds from urban and peri-urban Dhaka, the capital city of Bangladesh.
Patients attending this hospital are first assessed by an experienced triage nurse, which includes assessment of the type of diarrhea and degree of dehydration, and presence of other health problems including ALRI/ pneumonia, severe malnutrition, impaired mental status (convulsion), and sepsis. The non-diarrhoeal patients have been redirected to other appropriate hospitals in the city. Based on an assessment of diarrhoeal patients, those with uncomplicated illness without signs of dehydration are referred to the Out-Patient Department (OPD) for 4-5 hours of observation, maintenance of hydration using ORS solution, and for provision of health education to the mothers/caregivers. Those with some and severe dehydration but without any associated health problems are admitted to Short Stay Ward (SSW) for correction of dehydration and maintenance of hydration using ORS and/or intravenous fluids, provision of antimicrobial therapy as appropriate, with an average stay of 24 hours. Those with associated complications of diarrhea and/or associated health problems are referred to a physician for assessing the need for admission to either the Longer Stay Ward (LSW) or Acute Respiratory Ward (ARI) or to the Intensive Care Word (ICU) depending on the clinical severity. The usual associated conditions include difficult respiration, cyanosis, apnoea, hypothermia or hyperthermia, marked lethargy or comatose condition, poor peripheral perfusion not attributable to severe dehydration. Participants hospitalized in SSW are assessed by hospital clinicians for possible admission to LSW and further workup and management. After admission to the LSW/ARI/SCU, the attending physician will obtain medical history, performs a thorough clinical examination, makes a problem list including differential diagnoses for each of them, arranges for required laboratory workups, and develops the treatment plan following standard guidelines of the hospital. Investigators will also perform bedside procedures such as sampling blood, performing lumbar punctures, etc. Oxygen saturation is determined by pulse oximeter when necessary, and blood glucose estimated by bedside Gluco Check machine in nearly all patients admitted to the LSW/ARI /SCU.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Investigators have completed the enrollment of 308 participants by the study endline. All the Serious adverse events have been reported appropriately to the Ethical Review Committee and the Data Safety and Monitoring Board (DSMB)
| Arm | Type | Receives |
|---|---|---|
| Ampicillin arm | Active comparator | Drug: AmoxicillinAmpicillin arm: Patients will receive four doses of parenteral Ampicillin and single dose of Gentamicin daily for 3-5 days |
| Amoxicillin arm | Experimental | Drug: AmoxicillinAmoxicillin arm: Patients will receive two doses of Amoxicillin and single dose of Gentamicin daily for 3-5 days |
Who may qualify
- Ages
- 2 months to 5 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- 1. WHO classified severe pneumonia
Key exclusion criteria (2 listed)
- Very sick children require mechanical ventilation
- Children with any congenital or structural defect
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AmoxicillinAlso: no other interventionTwice daily doses of injectable amoxicillin | Drug | Amoxicillin arm, Ampicillin arm |
Primary outcome
Treatment failure
Time frame: within 48 hours
Persistence of danger signs of severe pneumonia such as hypoxia, feeding difficulty, abnormal mentation after 48 hours or new appearance of danger sign within 24 hours
4 secondary outcomes
Time of resolution or recovery from pneumonia period for pneumonia
Time frame: 48 hours
Total length of hospitalization
Time frame: 3-5 days
Nosocomial infection
Time frame: 7 days
Post discharge morbidity
Time frame: 30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2021.
- Background: PubMed 33136058Shahrin L, Chisti MJ, Shahid ASMSB, Rahman ASMMH, Islam MZ, Afroze F, Huq S, Ahmed T. Injectable Amoxicillin Versus Injectable Ampicillin Plus Gentamicin in the Treatment of Severe Pneumonia in Children Aged 2 to 59 Months: Protocol for an Open-Label Randomized Controlled Trial. JMIR Res Protoc. 2020 Nov 2;9(11):e17735. doi: 10.2196/17735.
- Individual participant dataSharing planned: No
Related trials for Treatment Failure
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 1
Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia
Renal Failure Congenital, Congenital Renal Anomaly Nos
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Active, not recruitingPhase 1
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lubaba Shahrin, MBBS, FCPS principal investigator
Dhaka Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Amoxicillin in people with Treatment Failure and Lethargy, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment failure (time frame: within 48 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03369093, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2021.